Related Experiment Video
Updated: Jun 27, 2026
06:19
Screening Ion Channels in Cancer Cells
Published on: June 16, 2023
Small-molecule Bcl-2 antagonists as targeted therapy in oncology
Current Oncology (Toronto, Ont.)
|December 17, 2008
Summary
Cancer cells often evade apoptosis by upregulating pro-survival Bcl-2 proteins, leading to therapy resistance. Small-molecule Bcl-2 antagonists offer a strategy to overcome this block and selectively kill cancer cells.
Area of Science:
- Molecular Biology
- Cancer Biology
- Drug Discovery
Background:
- Pro-survival Bcl-2 proteins are upregulated in cancer cells, blocking apoptosis.
- This upregulation contributes to resistance against conventional cancer chemotherapeutics.
- Targeting pro-survival Bcl-2 proteins can overcome apoptosis resistance.
Purpose of the Study:
- To review the progress of small-molecule Bcl-2 antagonists in clinical trials.
- To highlight strategies for alleviating apoptosis blocks in cancer cells.
- To discuss the potential of Bcl-2 antagonists in cancer therapy.
Main Methods:
- Review of clinical trial data for small-molecule Bcl-2 antagonists.
- Analysis of Bcl-2 family protein interactions in apoptosis regulation.
- Discussion of cancer cell survival mechanisms and therapeutic resistance.
Main Results:
- Three small-molecule Bcl-2 antagonists have advanced into clinical evaluation.
- These antagonists aim to inactivate pro-survival Bcl-2 family members.
- Targeting Bcl-2 proteins offers a potential strategy to selectively kill cancer cells.
Conclusions:
- Small-molecule Bcl-2 antagonists represent a promising therapeutic strategy.
- Overcoming the apoptosis block in cancer cells can enhance treatment efficacy.
- Selective killing of malignant cells is achievable by targeting pro-survival pathways.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...